In the FUTURE-C-Plus phase II trial, patients with advanced previously untreated immune-enriched triple-negative breast cancer achieved an overall objective response rate of 81.3% with the combination of camrelizumab, famitinib, and nab-paclitaxel. This supports that the quantity of immune cells is important for identifying those with response to treatments combined with PD-1–targeting immunotherapy.

See related article by Chen et al., p. xxx

This content is only available via PDF.
You do not currently have access to this content.